Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

NCT ID: NCT05856864

Last Updated: 2024-04-15

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-06-01
• Study Completion Date: 2025-05-01

Brief Summary

To evaluate the efficacy Cadonilimab in combination with Ramucirumab for the treatment of advanced Hepatocellular Carcinoma that has failed at systemic therapy

Detailed Description

An open, single-arm, single-centre,Phase II clinical study evaluating Cadonilimab in combination with Ramucirumab for the treatment of advanced hepatocellular carcinoma that has failed at systemic therapy

Conditions

Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cadonilimab in Combination With Ramucirumab

Cadonilimab Injection 10mg/kg, intravenous drip ,q2w,

Group Type: EXPERIMENTAL

Cadonilimab Injection

Intervention Type: DRUG

Cadonilimab Injection, 10mg/kg, intravenous drip ,q2w,

Ramucirumab Injection

Intervention Type: DRUG

Ramucirumab Injection，8mg/kg, intravenous drip ,q2w,

Interventions

Cadonilimab Injection

Cadonilimab Injection, 10mg/kg, intravenous drip ,q2w,

Intervention Type: DRUG

Ramucirumab Injection

Ramucirumab Injection，8mg/kg, intravenous drip ,q2w,

Intervention Type: DRUG

Other Intervention Names

AK104

Eligibility Criteria

Inclusion Criteria

1. written informed consent signed prior to enrolment.

2. age > 18 years, both sexes

3. patients with histologically or pathologically confirmed intermediate to advanced hepatocellular carcinoma.

4. Previously received systemic drug treatment for HCC, with disease progression or intolerable toxicity

5. Child-Pugh A or B7

6. with measurable lesions (≥10 mm long diameter on CT scan for non-lymph node lesions and ≥15 mm short diameter on CT scan for lymph node lesions according to RECIST 1.1 criteria).

7. ECOG PS score: 0 to 1.

8. expected survival of >12 weeks.

9. function of vital organs in accordance with the following requirements (excluding the use of any blood components and cell growth factors within 14 days).

1) Blood count. Neutrophils ≥ 1.5 x 109/L Platelet count ≥ 60×109/L haemoglobin ≥ 90 g/L. 2) Liver and kidney function. Serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 50 ml/min (Cockcroft-Gault formula).

total bilirubin (TBIL) ≤ 3 times the upper limit of normal (ULN) Glutamic aminotransferase (AST) or glutamic aminotransferase (ALT) levels ≤ 10 times the upper limit of normal (ULN); urine protein < 2+; if urine protein ≥ 2+, 24-hour urine protein quantification must show ≤ 1 g of protein.

10. normal coagulation function, no active bleeding or thrombotic disease

1. International normalised ratio INR ≤ 1.5 x ULN.

2. partial thromboplastin time APTT ≤ 1.5 x ULN.

3. prothrombin time PT ≤ 1.5 x ULN. 11. Female patients who are non-surgically sterilised or of childbearing age are required to use a medically approved contraceptive (e.g. IUD, pill or condom) during and for 3 months after the end of the study treatment period; female patients of childbearing age who are non-surgically sterilised must have a negative serum or urine HCG test within 7 days prior to study entry; and must be non-lactating; male patients who are non-surgically sterilised or of childbearing age Patients, need to agree to use a medically approved form of contraception with their spouse during and for 3 months after the end of the study treatment period.

12. The subject is voluntarily enrolled in the study, is compliant and cooperates with safety and survival follow-up

Exclusion Criteria

Patients with any of the following are not eligible for enrollment in this study.

1. Subjects with previous or concurrent other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix).

2. the subject has received previous immunotherapy other than anti-PD-1/PD-L1 monoclonal antibody; the subject is known to have a previous allergy to macromolecular protein agents, or is known to be allergic to the components of the drug applied.

3. The subject has any active autoimmune disease or history of autoimmune disease (e.g. the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enterocolitis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism, previous thyroid surgery cannot be included; the subject has vitiligo or has complete remission of asthma in childhood and in adulthood (subjects who do not require any intervention can be included; subjects with asthma requiring medical intervention with bronchodilators cannot be included).

4. subjects who are on immunosuppressive, or systemic, or absorbable topical hormone therapy for immunosuppressive purposes (doses >10 mg/day of prednisone or other isotonic hormones) and who continue to use them within 2 weeks prior to enrolment

5. have clinically symptomatic ascites or pleural effusion requiring therapeutic puncture or requiring frequent drainage of ascites (≥1 time/month)

6. subjects with clinically symptomatic cardiac conditions or diseases that are not well controlled, such as (1) NYHA class 2 or higher heart failure (2) unstable angina pectoris (3) previous myocardial infarction within 1 year (4) patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention

7. subjects with active infection or unexplained fever >38.5 degrees during screening and prior to the first dose (subjects with fever arising from a tumour may be enrolled, as judged by the investigator)

8. patients with previous and current objective evidence of a history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, or severely impaired lung function

9. subjects with congenital or acquired immune deficiency, e.g. HIV infection

10. subjects who have received a live vaccine less than 4 weeks prior to study drug administration or possibly during the study period

11. subjects with a known history of psychotropic substance abuse, alcoholism or drug use

12. patients who are unable to administer the drug orally

13. have received herbal or proprietary Chinese medicine with an anti-tumour indication within 2 weeks prior to the first dose .

14 Patients who, in the opinion of the investigator, should be excluded from the study, for example, subjects who, in the judgment of the investigator, have other factors that may force the study to be terminated, e.g., other serious illnesses (including psychiatric illnesses) requiring comorbid treatment, severe fundic esophageal varices, serious laboratory test abnormalities, accompanying family or social factors that would compromise the safety of the subject, or the collection of data and samples.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tianjin Medical University Cancer Institute and Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Huikai Li, MD

Role: STUDY_DIRECTOR

Tianjin Cancer Hospital Airport Hospital

Locations

Tianjin Cancer Hospital Airport Hospital

Tianjin, Tianjin Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Huikai Li, MD

Role: CONTACT

tjchlhk@126.com

18622228639

Yang Liu, MD

Role: CONTACT

17694950696

Facility Contacts

Huikai Li, MD

Role: primary

tjchlhk@126.com

18622228639

Yang Liu, MD

Role: backup

17694950696

Other Identifiers

AK104-IIT-C-N1-0042

Identifier Type: -

Identifier Source: org_study_id